• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA panel recommends approval of Staar Surgical’s novel eye implant

FDA panel recommends approval of Staar Surgical’s novel eye implant

March 14, 2014 By Ingrid Mezo

FDA panel recommends XXX approval of first-in-kind eye implant

An FDA panel today voted today to recommend approval for Staar Surgical’s (NSDQ:STAA) novel Visian Toric implantable collamer lens for treatment of myopic astigmatism in adults aged 21-45.

If FDA follows its panel’s recommendation and grants marketing approval for Visian Toric, California ophthalmic devices maker Staar Surgical will hold the only lens approved in the U.S. for placement in the posterior chamber (ciliary sulcus) of the phakic eye for myopia and astigmatism.

Panelists voted 5 in favor that there is a reasonable assurance of safety, with 1 no and 3 abstentions. They voted 7 in favor of effectiveness, with 1 no and 1 abstention. On Visian Toric’s benefits outweighing risks, 6 panelists voted yes and 3 abstained.

This is not Visian Toric’s 1st time at bat with the FDA, according to background materials released ahead of the meeting. The federal watchdog agency in 2012 denied marketing approval for the lens after Staar Surgical failed to meet requirements for post-approval study data. Visian Toric was initially approved in 2005, subject to post-approval study data from 3 studies.

The 1st post-approval study was to monitor for device-related corneal endothelial cell loss for 5 years and Staar was asked to provide yearly reports on this data. FDA in 2011 approved Staar’s report on the results of this study, but ultimately denied the company’s proposed device labeling revision in 2012 "based on a number of concerns regarding the analysis used to describe the endothelial cell density (ECD) development. The applicant has yet to provide FDA with their response to the labeling concerns," the agency stated.

Staar was also tasked with monitoring adverse events under conditions of general use in a second 5-year post-approval study of Visian Toric, including cataract formation, corneal decompensation, persistent elevated retinal detachment, chronic uveitis and secondary surgical interventions (e.g., lens exchange, lens explantation, repositioning). This 2nd study, which is ongoing, involved enrollment of 5,000 U.S. patients in order to obtain 5-year follow-up on at least 2,000 patients.

Finally the company was asked to conduct a pre- and post-operative axial length measurement sub-study to determine whether Visian Toric affects this measurement. The FDA in 2011 approved Staar Surgical’s proposed updates to device labeling based on this 3rd sub-study.

Visian Toric is already approved in a number of countries around the world, and Staar recently notched Japanese regulatory approval for a new version of the lens implant featuring CentraFLOW technology, which the company called a "key driver to our growth of Visian ICL revenues the past several quarters," according to a company press statement. CentraFLOW allows physicians to treat a larger range of patients with the Visian ICL, expanding to myopia starting at -3.0 diopters, up from the current range at -5.0 diopters, according to a press release.

Filed Under: Food & Drug Administration (FDA), News Well, Optical/Ophthalmic, Pre-Market Approval (PMA), Regulatory/Compliance Tagged With: STAAR Surgical Co

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy